新規抗てんかん薬血中濃度測定の内製化による効果

末次 王卓, 増田 智先, 江頭 伸昭, 山本 奈々絵, 重松 智博, 小林 大介, 土谷 祐一, 中山 由理恵, 辻 敏和, 渡邊 裕之, 金谷 朗子

研究成果: Contribution to journalArticle査読

抄録

<p>For many of the novel antiepileptics, immunoassays, used for routine therapeutic drug monitoring (TDM), cannot be used. We could monitor eight novel antiepileptics using an LC/MS method since July 2017. The purpose of this study was to evaluate the significant changes associated with the transition from outsourcing to in-hospital monitoring of novel antiepileptics. The number of measurements of novel antiepileptics was significantly increased during the first (<i>p</i><0.01) and second (<i>p</i><0.001) years of in-hospital monitoring as compared to that one year prior to in-hospital monitoring which was outsourced. The proportion of measurements of novel antiepileptics to all antiepileptics was 19.7%, 31.1%, and 38.4% during outsourcing, and first, and second years of in-hospital monitoring, respectively. The measurement cost was significantly reduced during the first (<i>p</i><0.001) and second (<i>p</i><0.001) years of in-hospital monitoring as compared to that during outsourcing. In addition, the revenue from TDM of antiepileptic drugs was significantly increased during the first (<i>p</i><0.05) and second (<i>p</i><0.01) years of in-hospital monitoring as compared with that during outsourcing. In conclusion, the switch from outsourcing to in-hospital monitoring led to an increase in the number of orders, a reduction in the measurement-related expenses of novel antiepileptics, and an increase in the revenue from TDM of antiepileptic drugs, which could promote the proper use of novel antiepileptics through TDM.</p>
寄稿の翻訳タイトルSignificant Changes Associated with the Transition from Outsourcing to In-hospital Therapeutic Drug Monitoring of Novel Antiepileptics
本文言語Japanese
ページ(範囲)1035-1040
ページ数6
ジャーナルYakugaku Zasshi
140
8
DOI
出版ステータス出版済み - 2020

フィンガープリント 「新規抗てんかん薬血中濃度測定の内製化による効果」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル